VICORE PHARMA HOLDING AB

Vicore Pharma shares rise 3.73 % as Phase 2b buloxibutid trial passes futility analysis, promising mid‑2027 results and 2028 cash runway.

Vicore Pharma’s recent 3.73 % rally amid a 10.62 % month‑low hints at upside if its anti‑inflammation and cardiovascular pipeline gains traction, offering a potential rebound near the 200‑day SMA.